Plasmin-a2-plasmin inhibitor complex in plasma of patients with thromboembolic diseases.
Plasmin generation in vivo was assessed by measuring plasma levels of plasmin-a2-plasmin inhibitor complex (PAP) with an ELISA in 42 patients with arterial or venous thromboembolic diseases. Plasma concentration of PAP was markedly elevated in patients with venous thromboembolic diseases during acute illness (3.32 +/- 3.71 ug/ml, mean +/- SD) as compared to healthy subjects (0.24 +/- 0.13 ug/ml, n = 14), while it was nearly normal (0.30 +/- 0.13 ug/ml) in patients with venous thromboembolic diseases in chronic stage. Patients with arterial thromboembolism had modestly elevated PAP; 1.05 +/- 0.77 ug/ml during acute episode, and 0.84 +/- 0.40 ug/ml in chronic stage. These results indicate that excessive activation of fibrinolytic system (plasmin generation in vivo) occurs actually in many patients with thrombotic diseases, especially in venous thromboembolic diseases during acute illness.
Wada
K
K
First Department of Internal Medicine, Niigata University School of Medicine, Japan.
Takahashi
H
H
Tatewaki
W
W
Takizawa
S
S
Shibata
A
A
D000208:Acute Disease; D000933:Antifibrinolytic Agents / Q000097:blood*; D002908:Chronic Disease; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005341:Fibrinolysin / Q000097:blood*; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D000073718:Pancreatitis-Associated Proteins; D013923:Thromboembolism / Q000097:blood*; D013924:Thrombophlebitis / Q000097:blood; D000979:alpha-2-Antiplasmin
D000933:Antifibrinolytic Agents; D000073718:Pancreatitis-Associated Proteins; C000612141:REG3A protein, human; D000979:alpha-2-Antiplasmin; C037742:plasmin-plasmin inhibitor complex; D005337:Fibrin; D005341:Fibrinolysin